Somnera

Somnera is a privately-held sleep solutions and connected health innovator focused on improving the lives of millions of patients suffering from Obstructive Sleep Apnea (OSA). The company secured its first FDA clearance in 2018, followed by the clearance of its commercial-ready Somnera™ System in June 2020. The Somnera System is small, lightweight, and easy to use, ushering in a new era of sleep for OSA patients. Somnera’s technology is cloud-connected, enabling the latest advances in cloud-based data analytics, patient engagement, and automated reorder/subscription models. Somnera holds 6 issued US patents, has completed two randomized clinical studies demonstrating equivalent effectiveness to CPAP, and will launch in the US in October 2020. Somnera’s dedicated and experienced management team is poised to capture share in the $35B available market for better OSA therapies and provide outstanding return to its shareholders. For more information, or to be one of the first to own a Somnera System, check us out on the web at www.somnera.com.

Today, over 50% of the patients who start CPAP abandon it because it is stigmatizing, uncomfortable, and difficult to use. The elegant and easy to use Somnera System is complemented by new features designed to engage and delight our customers. Sleep apnea is a serious problem: it affects 1 billion adults globally and is one of the largest, most poorly served and economically costly diseases in the world. Left untreated, sleep apnea doesn’t just make you tired, it also makes a host of other conditions worse, from diabetes to dementia. It is also associated with a three-fold increase in all-cause mortality. The Somnera System has been strategically developed to fit within existing diagnosis, treatment, and reimbursement pathways. It uses connectivity to engage customers, facilitate outstanding Customer Customer Lifetime Value, and provide endless possibilities for the future. The US FDA cleared the Somnera System in June of 2020.

Company’s Keywords: